Efficacy and safety of remimazolam for sedation during gynaecologic procedures: a systematic review and meta-analysis
Open Access
- 27 October 2025
- journal article
- review article
- Published by Taylor & Francis in Annals of Medicine
- Vol. 57 (1) , 2568985
Abstract
The efficacy of remimazolam compared to propofol for sedation during gynaecologic procedures remains unknown, due to the increased severity of pain associated with these procedures. Therefore, a systematic review and meta-analysis was conducted to address this issue. The protocol has been registered with PROSPERO, number CRD42024511475. Medline/PubMed, Cochrane Library, Embase, Scopus and Web of Science were searched to identify randomized controlled trials (RCTs) covering the period up to 10 January 2025. The primary outcomes comprised the success rate of sedation and the incidence of body movement. Secondary outcomes included recovery time and incidence of adverse effects (i.e. hypotension, bradycardia, respiratory depression, postoperative nausea and vomiting (PONV), dizziness, hiccup and injection pain). Nine RCTs (1129 patients) were included in this meta-analysis. There were no significant differences for the success rate of sedation (RR = 0.98, 95% confidence interval (CI) 0.96-1.00) or the incidence of body movement (RR = 1.03, 95% CI 0.49-2.14). Remimazolam had a lower incidence of adverse effects, including hypotension (RR = 0.21, 95% CI 0.11-0.41), bradycardia (RR = 0.12, 95% CI 0.02-0.97), respiratory depression (RR = 0.30, 95% CI 0.15-0.61), injection pain (RR = 0.06, 95% CI 0.02-0.17) and dizziness (RR = 0.29, 95% CI 0.10-0.82). However, remimazolam increased the incidence of hiccup (RR = 10.16, 95% CI 2.48-41.61). No significant differences were found regarding the recovery time (MD = 1.58, 95% CI -0.20 to 3.35) or the incidence of PONV (RR = 0.68, 95% CI 0.15-3.05). In gynaecologic procedures, remimazolam has comparable efficacy to propofol in the success rate of sedation and the incidence of body movement, while exhibiting superior respiratory and cardiovascular safety profiles. These findings should be cautiously generalized to other populations, and warrant further validation.Keywords
Funding Information
- Taizhou Enze Medical Centre (Group) Research Foundation (23EZC07)
This publication has 52 references indexed in Scilit:
- Pharmacokinetics and pharmacodynamics of the short-acting sedative CNS 7056 in sheepBritish Journal of Anaesthesia, 2010
- Comparison of the sedative properties of CNS 7056, midazolam, and propofol in sheepBritish Journal of Anaesthesia, 2009
- Pain control in first trimester surgical abortionCochrane Database of Systematic Reviews, 2009
- GRADE: an emerging consensus on rating quality of evidence and strength of recommendationsBMJ, 2008
- A modified test for small‐study effects in meta‐analyses of controlled trials with binary endpointsStatistics in Medicine, 2005
- Sympathetic and Hemodynamic Effects of Moderate and Deep Sedation with Propofol in HumansAnesthesiology, 2005
- Propofol: Therapeutic Indications and Side-EffectsCurrent Pharmaceutical Design, 2004
- Measuring inconsistency in meta-analysesBMJ, 2003
- The use of propofol for its antiemetic effect: A survey of clinical practice in the united statesJournal of Clinical Anesthesia, 2000
- Drug-Induced HiccupsAnnals of Pharmacotherapy, 1997